TWENTYEIGHT-SEVEN THERAPEUTICS
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.
TWENTYEIGHT-SEVEN THERAPEUTICS
Social Links:
Industry:
Biotechnology Developer Platform Health Care Life Science Therapeutics
Founded:
2016-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.twentyeight-seven.com
Total Employee:
11+
Status:
Active
Contact:
617-331-7523
Total Funding:
80 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics SSL By Default Global Site Tag HSTS Google Universal Analytics
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
HbO2 Therapeutics
HbO2 Therapeutics develops and manufactures oxygen carrying solutions.
HotSpot Therapeutics
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Quentis Therapeutics
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Johnson & Johnson Robotics and Digital Solutions
Johnson & Johnson Robotics and Digital Solutions investment in Series A - Twentyeight-Seven Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series A - Twentyeight-Seven Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Twentyeight-Seven Therapeutics
Vertex Ventures
Vertex Ventures investment in Series A - Twentyeight-Seven Therapeutics
MPM Capital
MPM Capital investment in Series A - Twentyeight-Seven Therapeutics
Longwood Fund
Longwood Fund investment in Series A - Twentyeight-Seven Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series A - Twentyeight-Seven Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Twentyeight-Seven Therapeutics
Vertex Ventures HC
Vertex Ventures HC investment in Series A - Twentyeight-Seven Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series A - Twentyeight-Seven Therapeutics
Official Site Inspections
http://www.twentyeight-seven.com Semrush global rank: 9.77 M Semrush visits lastest month: 318
- Host name: cloudproxy10153.sucuri.net
- IP address: 192.124.249.153
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Twentyeight-Seven Therapeutics"
Home - 28-7 28-7 [www.twentyeight-seven.com]
Our Therapies Restore Balance. We are explorers leading the revolution in RNA drug discovery to develop an entirely new class of therapies. We are identifying the chemical motifs to potently …See details»
Twentyeight-Seven Therapeutics - Crunchbase
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target …See details»
Twentyeight-seven, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Twentyeight-seven, Inc. of Watertown, MA. Get the latest business insights from Dun & Bradstreet.See details»
Twentyeight-Seven Therapeutics - Contacts, Employees, Board …
Organization. Twentyeight-Seven Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. …See details»
28-7 - Company Profile - Tracxn
Nov 5, 2024 TWENTYEIGHT-SEVEN, INC. Feb 02, 2016--513. Get your free copy of 28-7's company profile. GET COMPANY PROFILE. 28-7's funding and investors. How much funding …See details»
TwentyEight-Seven Inc - Company Profile and News
TwentyEight-Seven, Inc. operates as a biotechnology firm. The Company focuses on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.See details»
Twentyeight-Seven Therapeutics: A One Pager for …
Aug 17, 2020 Twentyeight-Seven Therapeutics (28-7) are explorers leading the revolution in RNA drug discovery to develop an entirely new class of therapies, beginning with a novel pipeline of microRNAs designed to target regulatory …See details»
Twentyeight-Seven Therapeutics Company Profile - Craft
Twentyeight-Seven Therapeutics is a biotechnology company focused on the modulation of non-coding RNA function to treat cancer and other human diseases. The Company is targeting …See details»
Twentyeight-Seven Therapeutics - Funding, Financials
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . May 9, 2019: Series A - …See details»
Twentyeight-Seven Therapeutics - Overview, News & Similar
May 8, 2019 Twentyeight-Seven Therapeutics, a Watertown, MA-based biotechnology company focused on the modulation of RNA to treat cancer and other human diseases, raised $15m in …See details»
Twentyeight-Seven Therapeutics Information - RocketReach
Twentyeight-Seven Therapeutics is based in Watertown, Massachusetts. Top Twentyeight-Seven Therapeutics Employees Edward Darr Vice President - Finance and Operations at …See details»
Redona Therapeutics — Sofinnova Partners
Redona Therapeutics (formerly Twentyeight-Seven Therapeutics) is a biotechnology company focused on the modulation of RNA to treat cancer and other human diseases. Targeting RNA …See details»
Top European VC leads 28-7’s Series A extension with $15 million …
Back to News 05/09/2019 Top European VC leads 28-7’s Series A extension with $15 million and brings financing to over $80 million. PARIS–(BUSINESS WIRE)–Sofinnova Partners, a leading …See details»
811868742 TWENTYEIGHT-SEVEN, INC. Employer Identification
TWENTYEIGHT-SEVEN, INC. BUSINESS ADDRESS EIN 811868742 An Employer Identification Number (EIN) is also known as a Federal Tax Identification Number, and is used to identify a …See details»
CLK (Twentyeight-Seven) - Drug Targets, Indications, Patents
CLK(Twentyeight-Seven): a CLK modulators Drug, Initially developed by Redona Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Mechanism: CLK modulators(Clk dual …See details»
28-7 launches to boost anticancer microRNA | C&EN Global …
Sep 17, 2018 Twentyeight-Seven Therapeutics (28-7) is the latest start-up to launch with the goal of developing drugs that tackle the tricky interface between RNA and proteins. And it has …See details»
Looking beyond cancer, Twentyeight-Seven Therapeutics bumps …
May 10, 2019 By targeting Lin28, Twentyeight-Seven hopes to boost Let-7, thereby curbing the translation of oncogenes within cells. RELATED: 28-7 Therapeutics raises $65M for cancer …See details»
News - 28-7
News 09/06/2018 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNAs . Founded in 2016, the company’s core technology comes from four Harvard Medical …See details»
TwentyEight Seven Events - Facebook
TwentyEight Seven Events. 199 likes. Welcome to TwentyEight Seven. We love weddings... but we love the wedding planning process even more!See details»